{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-022588","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.066775+00:00","generated_at":"2026-06-24T00:00:13.180998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aerovate Therapeutics reports Q2 net loss of $12.0M; cash runway into H2 2025","bullets":["Net loss $12.0M in Q2 2022 vs $5.8M in Q2 2021; R&D expenses $8.4M, G&A $3.9M.","Cash and investments $152.0M as of June 30, 2022; expected to fund operations into H2 2025.","IMPAHCT Phase 2b/Phase 3 trial ongoing; topline Phase 2b data expected Q4 2023 or Q1 2024.","Phase 1 data for AV-101 showed well-tolerated and reduced systemic exposure vs oral imatinib.","Strengthened management: Stephen Yu joined as SVP Quality with 20+ years pharma experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-022588","json":"https://secwatch.observer/filing/0001493152-22-022588.json","markdown":"https://secwatch.observer/filing/0001493152-22-022588.md","text":"https://secwatch.observer/filing/0001493152-22-022588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000149315222022588/0001493152-22-022588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000149315222022588/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:00:13.180998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}